TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17544497

Group type: EXPERIMENTAL
Intervention: Three cycles of platinum-based chemotherapy followed by surgery (CT-S)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Surgery alone (S)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Overall survival (CT-S)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Overall survival (combined systematic review including present result)
Number of subjects: 519
Study: 15099420

Group type: EXPERIMENTAL
Intervention: Maintenance interpersonal psychotherapy for 2 years
Number of subjects: 125
Study: 11448378

Group type: COMPARATOR
Intervention: QI-therapy
Number of subjects: 1299

Group type: COMPARATOR
Intervention: QI-meds
Number of subjects: 1299

Group type: COMPARATOR
Intervention: UC
Number of subjects: 1299
Study: 9710334

Group type: EXPERIMENTAL
Intervention: Insertion gain fittings
Number of subjects: 40

Group type: COMPARATOR
Intervention: Median ear corrected coupler fittings
Number of subjects: 40
Study: 7697844

Group type: EXPERIMENTAL
Intervention: Directional atherectomy
Number of subjects: 1012
Study: 2540789

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (M series: 131 patients)
Number of subjects: 497

Group type: COMPARATOR
Intervention: No maintenance chemotherapy (NoM series: 134 patients)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Patients with complete response to initial chemotherapy (99 patients)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Initial chemotherapy
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Overall survival at 1 year
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Overall survival at 2 years
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Overall survival at 3 years
Number of subjects: 497
Study: 836131

Group type: EXPERIMENTAL
Intervention: Foster care preparation
Number of subjects: 572

Group type: COMPARATOR
Intervention: Continued hospitalization
Number of subjects: 572
Study: 29994983

Group type: EXPERIMENTAL
Intervention: Women aged 17-24 years
Number of subjects: 136

Group type: COMPARATOR
Intervention: Participants aged 11-16 years
Number of subjects: 136

Group type: COMPARATOR
Intervention: Self-report and SD of tacrolimus trough levels
Number of subjects: 136
Study: 28375507

Group type: EXPERIMENTAL
Intervention: Group A (Tdap 3-4 weeks before PCV13 and MCV4)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Group B (All three vaccines concurrently)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Group C (PCV13 and MCV4 3-4 weeks before Tdap)
Number of subjects: 166

Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 166
Study: 25234823

Group type: EXPERIMENTAL
Intervention: Immediate cognitive-behavioral intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups (post-intervention)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Immediate intervention group (2-year follow-up)
Number of subjects: 104
Study: 22158530

Group type: EXPERIMENTAL
Intervention: Preferred side of approach
Number of subjects: 83

Group type: COMPARATOR
Intervention: Non-preferred side of approach
Number of subjects: 83
Study: 21575983

Group type: EXPERIMENTAL
Intervention: Carboplatin-pegylated liposomal doxorubicin (CD)
Number of subjects: 976

Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel (CP)
Number of subjects: 976
Study: 19566763

Group type: EXPERIMENTAL
Intervention: Perospirone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 66
Study: 17007024

Group type: EXPERIMENTAL
Intervention: PegIFN‐alpha2a 180 mg subcutaneously once weekly for a year + Ribavirin 1200 mg
Number of subjects: 73

Group type: COMPARATOR
Intervention: IFN alpha‐2a 3 MU 3 times weekly + Ribavirin 1200 mg
Number of subjects: 73
Study: 15017671

Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rifampin (300 or 600 mg daily)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 180
Study: 11200367

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 11
Study: 9292183

Group type: EXPERIMENTAL
Intervention: Topical nasal steroid (budesonide)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 30
Study: 7944323

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CHG) products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iodophor product
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parachlorometaxylenol products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol product
Number of subjects: 0
Study: 3336257

Group type: EXPERIMENTAL
Intervention: Topical clindamycin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31249023

Group type: EXPERIMENTAL
Intervention: Digital health tool Smart Client (1 welcome call, 13 program calls, 3 quiz calls)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 565
Study: 28256104

Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg/day for 3 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 25438964

Group type: EXPERIMENTAL
Intervention: Brain 101 intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study: 22511592

Group type: EXPERIMENTAL
Intervention: UFH+GPI (initial UFH bolus: 60 IU kg(‐1), target ACT: 200‐250 sec)
Number of subjects: 1624
Study: 22092941

Group type: EXPERIMENTAL
Intervention: Light scoring using a scalpel
Number of subjects: 101

Group type: COMPARATOR
Intervention: Marking using a gentian violet marker
Number of subjects: 101
Study: 19935373

Group type: COMPARATOR
Intervention: Standard exposure everolimus (C0 3‐8 ng/mL) with low‐concentration cyclosporine A (C2 maintenance levels 350‐500 ng/mL)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Higher exposure everolimus (C0 8‐12 ng/mL) with very low‐concentration cyclosporine A (C2 maintenance levels 150‐300 ng/mL)
Number of subjects: 285
Study: 16796694

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (400 mg orally twice daily)
Number of subjects: 20
Study: 15273706

Group type: EXPERIMENTAL
Intervention: Intermediate-dose cyclophosphamide (2 g/m(2)) plus lenograstim at 5 micrograms/kg (Cyclo-G-CSF group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Lenograstim alone at 10 micrograms/kg (G-CSF group)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Intermediate-dose cyclophosphamide plus lenograstim (Cyclo-G-CSF group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Lenograstim alone (G-CSF group)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study: 10860226

Group type: EXPERIMENTAL
Intervention: Low-tidal-volume ventilation (6 mL/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional-tidal-volume ventilation (12 mL/kg)
Number of subjects: 0
Study: 9054848

Group type: EXPERIMENTAL
Intervention: Maximal medical therapy
Number of subjects: 256
Study: 8346750

Group type: EXPERIMENTAL
Intervention: Dacron prosthetic ligament reconstruction
Number of subjects: 84
Study: 2871049

Group type: EXPERIMENTAL
Intervention: Dezocine 5 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Dezocine 10 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Dezocine 2.5 mg
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 31494070

Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the dlPFC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APTD (acute phenylalanine/tyrosine depletion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of APTD and anodal tDCS
Number of subjects: 0
Study: 29778750

Group type: EXPERIMENTAL
Intervention: Continuous crystalloid cardioplegia via vein grafts plus intermittent blood cardioplegia through aortic root (group 1)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Antegrade blood cardioplegia alone (group 2, control)
Number of subjects: 223
Study: 27513162

Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (BCP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Autogenous bone (AB)
Number of subjects: 10
Study: 24929926

Group type: EXPERIMENTAL
Intervention: Short-term Cognitive-Behavioral Treatment (CBT)
Number of subjects: 41
Study: 23452265

Group type: EXPERIMENTAL
Intervention: Hypercapnic hyperpnoea
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study: 21046360

Group type: EXPERIMENTAL
Intervention: Combined lifestyle intervention (diet, exercise, and diet plus exercise)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Combined lifestyle intervention
Number of subjects: 577
Study: 18955835

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (154 mEq/l infusion)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Sodium chloride (0.9% solution)
Number of subjects: 145
Study: 16551862

Group type: EXPERIMENTAL
Intervention: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) at 1,200 mg m(‐2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA)
Number of subjects: 15
Study: 12812667

Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation
Number of subjects: 1435

Group type: COMPARATOR
Intervention: Traditional ventilation
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: Combined analysis of all studies
Number of subjects: 1435
Study: 10839291

Group type: EXPERIMENTAL
Intervention: Active treatment in every arm
Number of subjects: 204

Group type: COMPARATOR
Intervention: No treatment arm
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Overall participation in RCTs
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Reasons for participating
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Reasons for declining participation
Number of subjects: 204
Study: 8706298

Group type: EXPERIMENTAL
Intervention: Estraderm 25
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Estraderm 50
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Combined Estraderm 25 and 50
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Estraderm 25 (age > 67 years)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Estraderm 50 (age < 67 years)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Estraderm 25 and 50 (overall)
Number of subjects: 196
Study: 1879994

Group type: EXPERIMENTAL
Intervention: Dapiprazole
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6120703

Group type: EXPERIMENTAL
Intervention: flunitrazepam 0.03 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: midazolam 0.15 mg/kg
Number of subjects: 30
Study: 31821592

Group type: EXPERIMENTAL
Intervention: DBT guided self-help (DBT-GSH)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: DBT unguided self-help (DBT-USH)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Unguided self-help control (USH)
Number of subjects: 71
Study: 31099927

Group type: EXPERIMENTAL
Intervention: Glycopyrronium tosylate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 28063503

Group type: EXPERIMENTAL
Intervention: Glutamine (0.25 g/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 25891654

Group type: EXPERIMENTAL
Intervention: Topical application of placental extract gel (group S)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 10
Study: 23810688

Group type: EXPERIMENTAL
Intervention: Shenqi particle (9.6 g 3 times per day)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Prednisone (1 mg/kg/d tapering to 0.17 mg/kg/d) and cyclophosphamide (total dose of 9-12 g/m²)
Number of subjects: 190
Study: 21616970

Group type: EXPERIMENTAL
Intervention: Attention deficit/hyperactivity disorder (ADHD)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 92
Study: 19291931

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: HRT plus cyclical etidronate
Number of subjects: 47

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 47
Study: 17251532

Group type: EXPERIMENTAL
Intervention: Uterine-artery embolization
Number of subjects: 157

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 157
Study: 15596580

Group type: EXPERIMENTAL
Intervention: 0.15% unoprostone isopropyl
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 11318054

Group type: EXPERIMENTAL
Intervention: Responses to nonspatial stimulus attribute of color
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonspatial responses of varying force
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticipated response effects
Number of subjects: 0
Study: 9129792

Group type: EXPERIMENTAL
Intervention: Exchange transfusions for neonatal hyperbilirubinemia
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Plasma bilirubin concentrations
Number of subjects: 11
Study: 8198981

Group type: EXPERIMENTAL
Intervention: Recombinant interleukin 2 (rIL-2) therapy
Number of subjects: 0
Study: 2885357

Group type: EXPERIMENTAL
Intervention: Terfenadine 300 mg bid for 3 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg bid for 3 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Chlorpheniramine 8 mg three times a day for 3 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 12
Study: 29248859

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 517

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 517

Group type: COMPARATOR
Intervention: Edoxaban and Warfarin
Number of subjects: 517
Study: 28494895

Group type: COMPARATOR
Intervention: Nitroglycerin infusion at a dose of 2‐5μg/kg/min
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Labetalol infusion at a dose of 0.5‐2mg/min
Number of subjects: 60
Study: 25604764

Group type: EXPERIMENTAL
Intervention: Ecosystem management intervention involving collection and elimination of small water holding containers and alteration or covering of large water tanks to prevent mosquito oviposition.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group not specified; no direct comparison group mentioned in the abstract.
Number of subjects: 20
Study: 24157162

Group type: EXPERIMENTAL
Intervention: Virtual reality simulator training (4 hours)
Number of subjects: 30
Study: 21129239

Group type: EXPERIMENTAL
Intervention: 250 mg ATP per day for 28 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1250 mg ATP per day for 28 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 5000 mg ATP per day for 28 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 5000 mg ATP on days 0 and 28
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0 mg ATP per day for 28 days (control)
Number of subjects: 32
Study: 18850558

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% and timolol 0.5% (fixed combination)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2% and timolol 0.5% (fixed combination)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brimonidine 0.2% (adjunctive therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dorzolamide 2% (adjunctive therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brimonidine/timolol (fixed combination)
Number of subjects: 0
Study: 16542051

Group type: EXPERIMENTAL
Intervention: ethinylestradiol 20mug/drospirenone 3mg
Number of subjects: 445

Group type: COMPARATOR
Intervention: ethinylestradiol 20mug/desogestrel 150mug
Number of subjects: 445
Study: 12816885

Group type: EXPERIMENTAL
Intervention: High density electrical mapping during AX-CPT task
Number of subjects: 0
Study: 11232987

Group type: EXPERIMENTAL
Intervention: Aspirin, ticlopidine, and further intravenous heparin infusion for 48 hours following primary coronary stenting (Group 1)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Aspirin and ticlopidine without further heparin therapy following primary coronary stenting (Group 2)
Number of subjects: 152
Study: 8626947

Group type: EXPERIMENTAL
Intervention: Ionic low osmolar contrast media
Number of subjects: 211

Group type: COMPARATOR
Intervention: Nonionic low osmolar contrast media
Number of subjects: 211
Study: 1460196

Group type: EXPERIMENTAL
Intervention: Peanut protein extracts treated with enzymes in the immobilized digestive enzyme assay system
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Soybean protein extracts treated with enzymes in the immobilized digestive enzyme assay system
Number of subjects: 12

Group type: COMPARATOR
Intervention: Peanut protein extracts subjected to thermal denaturation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Soybean protein extracts subjected to thermal denaturation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Chemical denaturation of peanut and soybean protein extracts
Number of subjects: 12
Study: 6368610

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 250 mg q.i.d.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31471248

Group type: EXPERIMENTAL
Intervention: TAU + MCT
Number of subjects: 50

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 50
Study: 30663788

Group type: EXPERIMENTAL
Intervention: SRP + EMD
Number of subjects: 38

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 38
Study: 28373523

Group type: EXPERIMENTAL
Intervention: Fire simulation training
Number of subjects: 19
Study: 26110891

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 6% v/v EtOH (alcohol)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 35
Study: 23464643

Group type: EXPERIMENTAL
Intervention: Acupuncture intervention consisting of eight sessions
Number of subjects: 60
Study: 21480681

Group type: EXPERIMENTAL
Intervention: Static and dynamic risk factors (alcohol dependence severity, treatment history, marital status, psychiatric symptoms, negative affect, craving, stress)
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Static risk factors (alcohol dependence severity, treatment history, marital status, psychiatric symptoms)
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Dynamic risk factors (changes in negative affect, craving, stress)
Number of subjects: 1383
Study: 19588684

Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural administration of bupivacaine with midazolam (group B)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Continuous thoracic epidural administration of bupivacaine (group A)
Number of subjects: 49
Study: 16816756

Group type: EXPERIMENTAL
Intervention: Lay-led intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychologist-led intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 12798539

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 microg every 6 hours (group 1)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg every 3 hours (group 2)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Loading dose of vaginal misoprostol 600 microg followed by oral misoprostol 200 microg every 3 hours (group 3)
Number of subjects: 84
Study: 10847283

Group type: EXPERIMENTAL
Intervention: Vicoprofen (ibuprofen 200 mg/hydrocodone 7.5 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine (acetaminophen 300 mg/codeine 30 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 8633398

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 1728377

Group type: EXPERIMENTAL
Intervention: Low doses of mitomycin C (5 mg/m2, intravenously) every 6 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard doses of mitomycin C (20 mg/m2, intravenously) every 6 weeks
Number of subjects: 67
Study: 6233879

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 950
Study: 31207908

Group type: EXPERIMENTAL
Intervention: Low-Fat Diet for Weight Loss (LFWL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low-Fat Diet for Weight Maintenance (LFWM)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Indomethacin (used in both diets)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Serum NO and CRP measurements (for both diets)
Number of subjects: 21
Study: 30201043

Group type: EXPERIMENTAL
Intervention: Tangbi Waixi (TW) decoction foot bath
Number of subjects: 640
Study: 27044304

Group type: EXPERIMENTAL
Intervention: Web-based relapse prevention program (e-SMARPP) consisting of six modules with tailored feedback from health care professionals and 8 weeks of self-monitoring.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-monitoring group (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based relapse prevention program (e-SMARPP)
Number of subjects: 0
Study: 24564877

Group type: EXPERIMENTAL
Intervention: Patient decision aid (PtDA) intervention
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual education (control)
Number of subjects: 142
Study: 23102183

Group type: EXPERIMENTAL
Intervention: Mindful Eating (MB-EAT-D)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Diabetes Self-Management Education (Smart Choices)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 20194878

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg/90 mg twice daily)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Clopidogrel (600 mg/75 mg once daily)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Ticagrelor therapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Clopidogrel therapy
Number of subjects: 98
Study: 17095943

Group type: EXPERIMENTAL
Intervention: Nutrient infusion of Ensure at 1 kcal/min
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nutrient infusion of Ensure at 2 kcal/min
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nutrient infusion in patients with feed intolerance
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nutrient infusion in patients with impaired renal function
Number of subjects: 31